Alpha IVF Group and subsidiary IVF Centres in Malaysia, Singapore further strengthen fertility treatments through modern tech, top-tier expertise

The group took home the Fertility Hospital of the Year - Malaysia and Technology Innovation of the Year - Malaysia accolades that the Healthcare Asia Awards.

Alpha IVF & Women’s Specialists has undergone significant growth since its inception as a single, standalone fertility centre in Selangor in 2011. It expanded its network of services to Penang in 2017 by establishing Genesis IVF & Women’s Specialists and to Singapore in 2019 under Alpha IVF Centre & Alpha Women’s Specialists Centre, culminating in the establishment of the parent company, Alpha IVF Group Berhad. Additionally, the Group is poised to welcome a new member, Alhaya Fertility Centre, by April 2024. This new advanced fertility centre will be situated in KPJ Damansara Specialists Hospital 2 in Bukit Lanjan, Kuala Lumpur, Malaysia.

The rapid growth of the group practices is propelled by the utilisation of cutting-edge technologies, resulting in high IVF success rates. By assembling a world-class team of highly qualified and experienced IVF and fertility specialists, alongside an international board of scientific members, embryologists, and geneticists, the group establishes a comprehensive system of systems aimed at optimising each patient's fertility potential. This is facilitated by modern fertility platforms equipped with state-of-the-art equipment, IVF laboratories, and other key technologies, all aimed at enhancing the efficiency of IVF.

Whilst each centre within the group has its unique strengths, they also collaborate to support one another in generating new referrals and case studies within their respective research and development areas.

This commitment to excellence is evidenced by the group's remarkable IVF success rates, averaging up to 87.5%, and the successful delivery of more than 7,000 IVF babies throughout their Centres. Moreover, there has been a notable growth of at least 15% in the influx of patients seeking fertility treatments in the Centres, both from international and local markets.

Alpha IVF Group's exceptional IVF success rates, comparable to those of leading global fertility Centres, are rooted in their unique synergy—a combination of a dedicated team of experts working hand-in-hand with the latest advancements in technology and active participation in R&D.

Their headquarters, Alpha IVF & Women’s Specialists in Kuala Lumpur, are actively pioneering research and innovative treatment procedures to improve their IVF outcomes. One of the latest advancements includes the integration of data compilation with Presagen from the early stages of AI development to the launch of the software for commercial use. Today, Alpha IVF Group and its subsidiaries' IVF Centres are avid users of AI in their embryo potential assessment, aimed at helping patients achieve better implantation and success rates.

The ongoing research in this area of AI, in collaboration with Presagen and other leading IVF centres around the world, led to the award for the best research paper of 2022 by RBMO. This recognition was bestowed for its international clinical study on the Life Whisperer Viability AI, further solidifying Alpha IVF Group's commitment to advancing fertility treatment through cutting-edge technology and collaborative research efforts.

In addition to these advancements, the Centres at Alpha IVF Group also utilise Cryotec® freezing technique, which stands out as the only method capable of achieving a 100% post-thaw survival rate for embryos/blastocysts. Furthermore, they employ PIEZO - ICSI for higher fertilisation rates and PGT (Preimplantation Genetic Testing) to genetically test embryos/blastocysts, all aimed at enhancing treatment outcomes.

By utilising these advanced technologies with their expertise, the fertility Centres at Alpha IVF Group ensure that each embryo has the best chance of successful development, maximising each patient’s opportunity to become a parent.

“The group continuously strives to further strengthen their position as a leading player in the industry. As a testament to this fact, they have produced close to 150 scientific papers that include approaches never attempted before in IVF,” the company’s Group Chief Marketing Officer, Mr. Tan Kay Pau said.

This remarkable success has been acknowledged by the Healthcare Asia Awards 2024, as Alpha IVF & Women’s Specialists secured the Fertility Hospital of the Year - Malaysia category win. Alpha IVF Group Berhad was also awarded the Technology Innovation of the Year - Malaysia accolade at the same awards programme. This recognition highlights the group's commitment to research and development, as well as its utilisation of advanced technologies.

The prestigious awards programme recognises exceptional healthcare providers that have redefined the standards of healthcare through their unwavering dedication to innovation, setting new industry benchmarks, and making substantial contributions to their communities.

The Healthcare Asia Awards is presented by Healthcare Asia Magazine. To view the full list of winners, click here. If you want to join the 2025 awards programme and be acclaimed for your organisation's remarkable initiatives and contributions to the healthcare industry, please contact Julie Anne Nuñez at [email protected].